Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Solid Biosciences (NASDAQ:SLDB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success [Yahoo! Finance]
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.